Clinical trials have traditionally fallen short when it comes to including people who are truly representative of the Alzheimer’s population. Recently successful efforts, however, are dispelling myths about the inclusion challenge. For example, among the 389 participants in the Evaluating Minority Patients with Actemra (EMPACTA) study approximately 84% were from Black, Hispanic, Native American, and other historically underrepresented groups. Key Question: What strategies successfully recruit, enroll, and retain participants who represent all of Us, especially those disproportionately affected?
